Novacyt S.A. (LON:NCYT – Get Free Report)’s stock price traded down 2.7% on Tuesday . The stock traded as low as GBX 33 and last traded at GBX 33. 73,397 shares were traded during mid-day trading, a decline of 68% from the average session volume of 229,547 shares. The stock had previously closed at GBX 33.90.
Novacyt Price Performance
The company has a debt-to-equity ratio of 44.73, a quick ratio of 4.46 and a current ratio of 4.74. The business’s 50 day simple moving average is GBX 40.61 and its 200-day simple moving average is GBX 36.81. The stock has a market capitalization of £24.70 million, a price-to-earnings ratio of -1.07 and a beta of 1.10.
Novacyt (LON:NCYT – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported GBX (33) EPS for the quarter. The firm had revenue of GBX 2,003 million during the quarter. Novacyt had a negative net margin of 135.96% and a negative return on equity of 121.30%.
Novacyt Company Profile
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.
Featured Articles
- Five stocks we like better than Novacyt
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
